Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(RS)-(±)-Sulpiride is a standard D2-like dopamine receptor antagonist.
S-enantiomer also available.
(RS)-(±)-Sulpiride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 341.42 |
公式 | C15H23N3O4S |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 15676-16-1 |
PubChem ID | 5355 |
InChI Key | BGRJTUBHPOOWDU-UHFFFAOYSA-N |
Smiles | CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 34.14 | 100 |
以下数据基于产品分子量 341.42。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.93 mL | 14.64 mL | 29.29 mL |
5 mM | 0.59 mL | 2.93 mL | 5.86 mL |
10 mM | 0.29 mL | 1.46 mL | 2.93 mL |
50 mM | 0.06 mL | 0.29 mL | 0.59 mL |
参考文献是支持产品生物活性的出版物。
Seeman and Van Tol (1993) DA D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective. Eur.J.Pharmacol. 233 173 PMID: 8097160
Seeman and Van Tol (1994) DA receptor pharmacology. TiPS 15 264 PMID: 7940991
Merck Index 12 9163
If you know of a relevant reference for (RS)-(±)-Sulpiride, please let us know.
关键词: (RS)-(±)-Sulpiride, (RS)-(±)-Sulpiride supplier, selective, D2-like, antagonists, Dopamine, Non-Selective, Receptors, dopaminergic, Non-selective, 0894, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 (RS)-(±)-Sulpiride 的部分引用包括:
Shin et al (2011) Exposure to extremely low frequency magnetic fields induces fos-related antigen-immunoreactivity via activation of DArgic d1 receptor. Neuropsychopharmacology 20 130 PMID: 22110371
Leyrer-Jackson (2017) Subtype-specific effects of DArgic D2 receptor activation on synaptic trains in layer V pyramidal neurons in the mouse prefrontal cortex. Physiol Rep 5 e13499 PMID: 29150590
Huang (2018) DA D1 Receptors Contribute Critically to the Apomorphine-Induced Inhibition of Form-Deprivation Myopia in Mice. Invest Ophthalmol Vis Sci 59 2623 PMID: 29847669
Zhang et al (2018) DA Receptor Subtypes Mediate Opposing Effects on Form Deprivation Myopia in Pigmented Guinea Pigs. Invest Ophthalmol Vis Sci 59 4441 PMID: 30193315
Matsui and Alvarez (2018) Cocaine Inhibition of Synaptic Transmission in the Ventral Pallidum Is Pathway-Specific and Mediated by Serotonin. Cell Rep 23 3852 PMID: 29949769
Holroyd et al (2015) Loss of feedback inhibition via D2 autoreceptors enhances acquisition of cocaine taking and reactivity to drug-paired cues. Brain 40 1495 PMID: 25547712
Zhang et al (2013) Sucrose produces withdrawal and DA-sensitive reinforcing effects in planarians. Physiol Behav 112-113 8 PMID: 23415661
您是否知道使用了 Tocris (RS)-(±)-Sulpiride 的优秀论文? 请告知我们.
平均评分: 4 (基于 2 条评论。)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
sulpiride (1 μM)
In voltammetry experiments measuring evoked dopamine release, quinpirole was used to activate D2 receptors to inhibit dopamine release. Sulpiride (600 nM) was applied afterward to reverse quinpirole effects.
We mix sulpiride at 2mM in ethanol. It goes into solution well.
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.